IRVINE, Calif. — GATC Health Corp. announced two additions to its leadership team as the company works to expand commercial adoption of its artificial intelligence platform across biotech, capital markets, and global pharmaceutical partners.
Mark Flather has joined as Senior Vice President of Business Development and Strategy, and Frederick (Fred) W. K. Brown has been named Senior Advisor, Pharma Partnerships & Strategy. The appointments are intended to accelerate adoption of the company’s Derisq™ AI risk prediction product and Operon™ AI platform.
“As we scale market adoption of Derisq and expand strategic partnerships around Operon, we are pleased to welcome proven experts in both capital allocation and global pharmaceutical execution,” said Gene O’Bryan, Chief Operations Officer of GATC Health. “Mark brings deep experience translating scientific value into investor confidence, and Fred brings decades of experience advancing and commercializing complex therapeutic portfolios. Together, they strengthen our ability to bridge AI innovation with real-world adoption.”
Flather brings more than 30 years of capital markets experience, including 13 years focused on drug discovery and biopharma. He previously held roles at two publicly traded companies and spent eight years at Hermes Advisors, an equity hedge fund. At GATC Health, he will lead global business development initiatives, leveraging his network and financial background to drive commercial growth and strategic partnerships.
“Biotech investors and analysts are under increasing pressure to make faster, more informed decisions,” said Flather. “Derisq introduces a quantitative layer of predictive intelligence that can materially improve how capital is allocated and how assets are prioritized. I’m excited to help integrate this capability into diligence workflows and strategic planning processes across the industry.”
Brown joins with decades of executive leadership experience across global pharmaceutical development and commercialization. He previously served as Global Head of Product Lifecycle at Hoffmann-La Roche, where he oversaw a multibillion-dollar portfolio and multiple major product launches. He also founded IBM’s Life Sciences Business Services Practice and co-founded Alkermes, contributing to early venture financing and corporate growth.
At GATC Health, Brown will advise on pharmaceutical strategy and institutional partnerships, helping position Operon™ and Derisq™ within large-scale R&D, lifecycle management, and M&A decision-making frameworks.
“GATC Health is uniquely positioned to help pharmaceutical companies optimize their search and evaluation, research and development and mergers and acquisition efforts from discovery all the way through NDA/BLA approval,” said Brown. “GATC’s validated AI technology offerings, especially the Derisq AI report, are ideal for evaluating asset prioritization at any phase of drug development with accurate assessment of risk and reward for each drug candidate. With both predictive and generative AI solutions, GATC broadly supports portfolio discovery, advancement and expansion internally and asset assessments externally.”
